Batoclimab, a experimental antibody designed to the IL-15 pathway, is gaining attention as a significant therapeutic option for individuals diagnosed with refractory ulcerative colitis and haven't responded adequately to existing drugs. Preclinical examination suggest that batoclimab can effectiv